Key takeaways
- Use function as a research starting point, not as proof that a person owns budget or final approval.
- For outsourced trials, the sponsor retains ultimate responsibility even when activities are transferred to a CRO.
- For contract manufacturing, FDA expects owner and facility responsibilities and final approvals to be documented in a quality agreement.
- Map technical, quality, commercial, and approval roles from account-specific evidence before targeting outreach.
There is no reliable title-only answer to who buys CRO, CDMO, or instrument services. Start with the function accountable for the work, then verify technical evaluation, quality and regulatory obligations, budget, procurement, and final approval for the specific account.
Why there is no single buyer title
Buyer targeting is harder in life science than in many industries because the same role carries different titles at different companies, and the same title can mean different things. A person who owns manufacturing decisions might be a VP of CMC at one company, a head of technical operations at another, and a founder wearing several hats at a third. Anchoring on a title string misses people who do the relevant job under a different name and picks up people whose title sounds right but who do not actually own the decision. The more reliable anchor is the function and the specific decision a person owns, which is the same principle the two-layer ICP for CROs and CDMOs uses for buyer fit.
Who owns the decision, by what you sell
The function closest to the work is a useful research starting point. It is not necessarily the budget holder or final approver:
Research clinical development and operations first, then map data, safety, regulatory, quality, finance, legal, and procurement roles as the scope requires. ICH GCP keeps ultimate trial responsibility with the sponsor even when activities move to a service provider.
Research CMC, technical operations, manufacturing, supply, and quality. FDA expects owner and contract facility roles, communication, change control, and final approvals to be documented; the commercial approver must still be identified account by account.
Start with the end user or lab function, then verify technical evaluation, facilities, IT, safety, quality, budget, and procurement requirements. Purchase authority cannot be inferred from title alone.
The persona playbooks go deeper on the first two: the GTM playbook for CROs and the GTM playbook for CDMOs each work through the buyer function alongside the signals and cadence that fit it.
The committee is rarely one person
More than one role may touch an outsourced-services decision. Use this as a discovery checklist, not a claim that every account has the same committee:
- The problem owner. The function closest to the need and therefore a useful starting point for discovery: clinical or development for CRO work, CMC or manufacturing for CDMO work, or an end-user function for an instrument.
- The technical evaluator. The person or group responsible for judging whether the offering fits; this may or may not be the same as the problem owner.
- The economic owner. Whoever holds the budget and the final sign-off, which sits higher in the organization as the spend grows.
- The gatekeeper. Quality, regulatory, or procurement, whose approval a deal has to clear even when they do not initiate it, and whose weight increases as a program nears commercial scale.
You do not always need to reach all four, but knowing which roles exist on a given account keeps you from mistaking a technical champion for the economic owner, or missing a quality or procurement gate that can stall a deal late.
How the committee shifts as a company matures
Company stage can change the work and roles involved, but it does not determine the committee on its own:
A small team may combine technical, budget, and approval roles, or may rely on board, investor, consultant, or parent-company controls. Confirm rather than assuming the founder is the sole buyer.
Dedicated clinical, CMC, quality, and operational roles may appear as work expands. Map which responsibilities are internal, outsourced, shared, or still held by executives.
Quality, supply, validation, finance, legal, and procurement requirements may become more formal. The exact committee and approval thresholds remain company-specific.
The practical implication is to map each account instead of applying a fixed committee size. A relevant leadership hire shows that the organization changed; it does not prove that a vendor search followed. The hiring signals guide covers how to read those moves.
What to do with this
Reach a function close to the problem, then ask who defines requirements, evaluates the work, owns quality or regulatory responsibilities, controls budget and terms, and gives final approval. Use titles only as search clues. Read alongside when biotech companies buy CRO and CDMO services, the picture is complete: what triggers the purchase, and who inside the company owns it.
Primary sources
- ICH E6(R3) Good Clinical Practice defines sponsor and service-provider responsibilities for transferred trial activities.
- FDA contract manufacturing quality-agreement guidance describes owner, contract-facility, quality, communication, change-control, and final-release responsibilities.